Apolipoprotein B compared with low-density lipoprotein cholesterol in the atherosclerotic cardiovascular diseases risk assessment

This review presses a now-familiar argument with particular clarity: ApoB beats LDL cholesterol as a risk marker because it counts the particles that actually cause disease.

The logic is mechanistic. Atherosclerosis begins when atherogenic particles lodge in the artery wall — and what matters is how many particles there are, not how much cholesterol each one carries. ApoB counts the particles directly; LDL-C is a surrogate that drifts with particle composition. The two diverge most in exactly the people at highest metabolic risk — diabetes, metabolic syndrome, high triglycerides — whose LDL particles run small and cholesterol-poor, so a “normal” LDL-C can hide a dangerous particle count. In those discordant cases, risk tracks ApoB, not LDL-C.

The practical takeaway is to fold ApoB into routine assessment, especially for metabolically unhealthy patients, where it catches risk LDL-C misses. The resistance is the entrenched dominance of LDL-C in guidelines, the perception that ApoB costs more, and the patchy availability of ApoB-specific targets.

We rate the evidence moderate: a narrative review drawing on strong external evidence (Mendelian randomization, cohorts, discordance analyses) but without its own systematic meta-analysis. Its clinical significance is high — it targets the residual risk in metabolic syndrome that LDL-C-centric strategies underserve, with an intervention (a single blood test) that is cheap and standardized.